King Pharmaceuticals KG Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid
Discontinued — last reported Q3 '25
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by King Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsForLossesAndLossAdjustmentExpense.
The official record: King Pharmaceuticals’s 10-Q, filed November 5, 2025, on SEC EDGAR. View the filing →
Ask your AI about King Pharmaceuticals's liability for unpaid claims and claims adjustment expense, claims paid.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is King Pharmaceuticals's liability for unpaid claims and claims adjustment expense, claims paid?
- King Pharmaceuticals (KG) reported liability for unpaid claims and claims adjustment expense, claims paid of $24.63M in Q3 2025.